AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30476916 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CaD) 500 mg, administered orally, 3 times per day for 3 months
Number of subjects: 100
Study 30476916 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 27434036 — intervention group
Group type: EXPERIMENTAL
Intervention: CT and CTX
Number of subjects: 257
Study 27434036 — intervention group
Group type: COMPARATOR
Intervention: CT alone
Number of subjects: 257
Study 27434036 — intervention group
Group type: EXPERIMENTAL
Intervention: Further treatment for progressive disease
Number of subjects: 257
Study 24090098 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (stationary cycling)
Number of subjects: 2
Study 24090098 — intervention group
Group type: COMPARATOR
Intervention: Non-aerobic exercise (stretching)
Number of subjects: 2
Study 22139410 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 g of pure βA reference solution (REF)
Number of subjects: 11
Study 22139410 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 g in slow-release βA tablets (TAB)
Number of subjects: 11
Study 22139410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study 19926442 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation Modification Program (IMP)
Number of subjects: 0
Study 19926442 — intervention group
Group type: COMPARATOR
Intervention: Interpretation Control Condition (ICC)
Number of subjects: 0
Study 18367385 — intervention group
Group type: EXPERIMENTAL
Intervention: SAT-diet
Number of subjects: 20
Study 18367385 — intervention group
Group type: COMPARATOR
Intervention: RO-diet
Number of subjects: 20
Study 15917030 — intervention group
Group type: EXPERIMENTAL
Intervention: Special training condition for pediatric residents
Number of subjects: 1770
Study 15917030 — intervention group
Group type: COMPARATOR
Intervention: Standard training condition for pediatric residents
Number of subjects: 1770
Study 12162502 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg SCT orally
Number of subjects: 8
Study 12162502 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg SCT orally
Number of subjects: 8
Study 12162502 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 microg SCT orally
Number of subjects: 8
Study 12162502 — intervention group
Group type: COMPARATOR
Intervention: 10 microg SCT intravenous infusion
Number of subjects: 8
Study 12162502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10467531 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (three 200-mg tablets per day)
Number of subjects: 234
Study 10467531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 7782354 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral electrical surface stimulation
Number of subjects: 159
Study 7782354 — intervention group
Group type: COMPARATOR
Intervention: Observation without treatment
Number of subjects: 159
Study 7782354 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model including Risser sign, apical level, and imbalance
Number of subjects: 159
Study 2224350 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation-advancement technique
Number of subjects: 108
Study 2224350 — intervention group
Group type: COMPARATOR
Intervention: Triangular flap technique
Number of subjects: 108
Study 638842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoke exposure
Number of subjects: 14
Study 638842 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 14
Study 31977640 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL + FRU
Number of subjects: 9
Study 31977640 — intervention group
Group type: EXPERIMENTAL
Intervention: MAL + FRU + PEC + ALG
Number of subjects: 9
Study 31977640 — intervention group
Group type: COMPARATOR
Intervention: MAL + GLU
Number of subjects: 9
Study 30386886 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6‐bevacizumab plus ip PTX
Number of subjects: 6
Study 30386886 — intervention group
Group type: EXPERIMENTAL
Intervention: CapeOX‐bevacizumab plus ip PTX
Number of subjects: 6
Study 30386886 — intervention group
Group type: EXPERIMENTAL
Intervention: ip PTX
Number of subjects: 6
Study 27932229 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily during weeks 1-3 of each 4-week cycle
Number of subjects: 573
Study 27932229 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily during weeks 1-3 of each 4-week cycle
Number of subjects: 573
Study 26052973 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin, steroids, and epinephrine (VSE) protocol
Number of subjects: 0
Study 26052973 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine alone
Number of subjects: 0
Study 23488277 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD/R pacing mode
Number of subjects: 117
Study 23488277 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI/R pacing mode
Number of subjects: 117
Study 23488277 — intervention group
Group type: EXPERIMENTAL
Intervention: VWVl/R pacing mode
Number of subjects: 117
Study 23488277 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 117
Study 20974751 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined microfinance and gender training intervention
Number of subjects: 0
Study 18940877 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily
Number of subjects: 40
Study 18940877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16489099 — intervention group
Group type: COMPARATOR
Intervention: ABP + RAP inputs
Number of subjects: 42
Study 16489099 — intervention group
Group type: COMPARATOR
Intervention: ABP + CVRI inputs
Number of subjects: 42
Study 15055892 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular treatment with clonidine 2 microg kg(‐1)
Number of subjects: 7
Study 15055892 — intervention group
Group type: COMPARATOR
Intervention: Control treatment with saline
Number of subjects: 7
Study 15055892 — intervention group
Group type: EXPERIMENTAL
Intervention: Block treatment with clonidine 2 microg kg(‐1)
Number of subjects: 7
Study 11245644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine pretreatment (before stenting)
Number of subjects: 1600
Study 11245644 — intervention group
Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 1600
Study 9335410 — intervention group
Group type: COMPARATOR
Intervention: benazepril, 10 mg, plus placebo (BZ10)
Number of subjects: 448
Study 9335410 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril, 10 mg, plus amlodipine, 2.5 mg (BZ10/AML2.5)
Number of subjects: 448
Study 9335410 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril, 10 mg, plus amlodipine, 5 mg (BZ10/AML5)
Number of subjects: 448
Study 8227238 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed medication-refill reminders
Number of subjects: 258
Study 8227238 — intervention group
Group type: EXPERIMENTAL
Intervention: Unit-of-use packaging
Number of subjects: 258
Study 8227238 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mailed medication-refill reminders and unit-of-use packaging
Number of subjects: 258
Study 8227238 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmaceutical care (Control)
Number of subjects: 258
Study 3804025 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (0.5 mg/patch)
Number of subjects: 7
Study 3804025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 7
Study 3804025 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of transdermal scopolamine and cimetidine
Number of subjects: 7
Study 3804025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31769592 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise cooling (fan turned on during recovery)
Number of subjects: 48
Study 31769592 — intervention group
Group type: COMPARATOR
Intervention: Control (no cooling during recovery)
Number of subjects: 48
Study 31281558 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Slow Breathing (DSB) program for 6 weeks
Number of subjects: 20
Study 31281558 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 28392320 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 10
Study 28392320 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-triphosphate (ATP)
Number of subjects: 10
Study 26241865 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 73
Study 26241865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 73
Study 26241865 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 73
Study 24047486 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy (CMT)
Number of subjects: 995
Study 24047486 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators (ICD)
Number of subjects: 995
Study 21558517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous epoetin alfa (60,000 U)
Number of subjects: 222
Study 21558517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 222
Study 19299145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular cocktail analgesic injection (morphine, bupivacaine, betamethasone)
Number of subjects: 80
Study 19299145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular cocktail analgesic injection
Number of subjects: 80
Study 19299145 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control Group)
Number of subjects: 80
Study 15894410 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic forms of Alzheimer's disease
Number of subjects: 49
Study 15894410 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic forms of Alzheimer's disease with presenilin-1 mutations
Number of subjects: 49
Study 15894410 — intervention group
Group type: COMPARATOR
Intervention: Sporadic cases of Alzheimer's disease
Number of subjects: 49
Study 15894410 — intervention group
Group type: COMPARATOR
Intervention: Non-diseased controls
Number of subjects: 49
Study 15545167 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal oil (10 ml, self-administered through a nasoduodenal feeding tube 3 times daily for 10 days)
Number of subjects: 19
Study 15545167 — intervention group
Group type: COMPARATOR
Intervention: Soy oil (10 ml, self-administered through a nasoduodenal feeding tube 3 times daily for 10 days)
Number of subjects: 19
Study 15545167 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal oil
Number of subjects: 19
Study 10896698 — intervention group
Group type: EXPERIMENTAL
Intervention: Total plasma homocysteine
Number of subjects: 46
Study 10896698 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum, red cell, and CSF folate, CSF S‐adenosylmethionine, and CSF monoamine metabolites
Number of subjects: 46
Study 10896698 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 healthy volunteers and 20 patients with neurological disorders)
Number of subjects: 46
Study 8761384 — intervention group
Group type: EXPERIMENTAL
Intervention: Elactocin (various infusion schedules: 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly, continuous 5 day intravenous infusion)
Number of subjects: 0
Study 1345261 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E)
Number of subjects: 28
Study 1345261 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (H)
Number of subjects: 28
Study 2865326 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of clorazepate at bedtime for two weeks
Number of subjects: 5
Study 2865326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 3033815 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran
Number of subjects: 18
Study 3033815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29746386 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT-T
Number of subjects: 55
Study 29746386 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT-WB
Number of subjects: 55
Study 29746386 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT
Number of subjects: 55
Study 29746386 — intervention group
Group type: COMPARATOR
Intervention: HIIT-T and MICT
Number of subjects: 55
Study 28152984 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy within 2 months
Number of subjects: 210
Study 28152984 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting (surgery after 12 months)
Number of subjects: 210
Study 24716586 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 2, 5 or 15mg twice daily
Number of subjects: 197
Study 24716586 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 197
Study 23264068 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Directed Therapy (GDT)
Number of subjects: 38
Study 23264068 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 38
Study 22035053 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction only (CR, N = 9)
Number of subjects: 30
Study 22035053 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction plus moderate‐intensity aerobic exercise (CRM, N = 13)
Number of subjects: 30
Study 22035053 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction plus vigorous‐intensity aerobic exercise (CRV, N = 8)
Number of subjects: 30
Study 22035053 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CRM and CRV (CRM+CRV)
Number of subjects: 30
Study 22035053 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction only (CR)
Number of subjects: 30
Study 22035053 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction plus moderate‐intensity aerobic exercise (CRM) and caloric restriction plus vigorous‐intensity aerobic exercise (CRV)
Number of subjects: 30
Study 18481290 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg BHT‐3009
Number of subjects: 267
Study 18481290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 16514109 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (nasal, 4 L . min(‐1))
Number of subjects: 9
Study 16514109 — intervention group
Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 9
Study 14696019 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 weeks)
Number of subjects: 653
Study 14696019 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 weeks)
Number of subjects: 653
Study 14696019 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 week baseline followed by 3 weeks treatment)
Number of subjects: 653
Study 11136301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine 10 mg orally for 7 days
Number of subjects: 10
Study 11136301 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 10
Study 9196517 — intervention group
Group type: EXPERIMENTAL
Intervention: BAYx 1005
Number of subjects: 10
Study 9196517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1348226 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group (R), n = 119
Number of subjects: 228
Study 1348226 — intervention group
Group type: COMPARATOR
Intervention: Hospital group (H), n = 109 (Control)
Number of subjects: 228
Study 1348226 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group (R)
Number of subjects: 228
Study 1348226 — intervention group
Group type: COMPARATOR
Intervention: Hospital group (H)
Number of subjects: 228
Study 1348226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 228
Study 4061800 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.75 mg/kg rectally
Number of subjects: 208
Study 4061800 — intervention group
Group type: COMPARATOR
Intervention: Mixture of diazepam 0.5 mg/kg, morphine 0.15 mg/kg, and hyoscine 0.01 mg/kg rectally
Number of subjects: 208
Study 30573298 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC-GLY (carboxymethylcellulose 1.0% and glycerin 0.9%)
Number of subjects: 188
Study 30573298 — intervention group
Group type: COMPARATOR
Intervention: CMC (carboxymethylcellulose 1.0%)
Number of subjects: 188
Study 29098286 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 607
Study 29098286 — intervention group
Group type: COMPARATOR
Intervention: Topical medications
Number of subjects: 607
Study 29098286 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Eye subscale of SHPC-18
Number of subjects: 607
Study 29098286 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Function subscale of SHPC-18
Number of subjects: 607
Study 29098286 — intervention group
Group type: EXPERIMENTAL
Intervention: SHPC-18
Number of subjects: 607
Study 24528667 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body resistance exercise leading to failure (3 sets with 8RM load)
Number of subjects: 14
Study 24528667 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body resistance exercise not to failure (3 sets with 70% of 8RM load)
Number of subjects: 14
Study 24528667 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body resistance exercise leading to failure
Number of subjects: 14
Study 24528667 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control session (30 min of seated rest)
Number of subjects: 14
Study 23324103 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet
Number of subjects: 72
Study 23324103 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet
Number of subjects: 72
Study 21213114 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate chew
Number of subjects: 0
Study 21213114 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk mineral chew
Number of subjects: 0
Study 21213114 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk drink
Number of subjects: 0
Study 21213114 — intervention group
Group type: COMPARATOR
Intervention: Placebo chew
Number of subjects: 0
Study 19743516 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (ATRA) for remission induction and/or maintenance
Number of subjects: 53
Study 19743516 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (no ATRA)
Number of subjects: 53
Study 19743516 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (both ATRA and conventional chemotherapy)
Number of subjects: 53
Study 17385465 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard medication and free-load bicycle exercise (FBE)
Number of subjects: 185
Study 17385465 — intervention group
Group type: COMPARATOR
Intervention: Standard medication only
Number of subjects: 185
Study 17385465 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 185
Study 15078738 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic training (2 days per week for 12 weeks, 30 to 45 min per session, anaerobic activities lasting 20 to 30 s)
Number of subjects: 20
Study 15078738 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaerobic training (after 12-week follow-up)
Number of subjects: 20
Study 15078738 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in normal daily activities)
Number of subjects: 20
Study 11802462 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnson & Johnson Health & Wellness Program
Number of subjects: 0
Study 9696444 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 40
Study 9696444 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 40
Study 7647718 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed pain patients
Number of subjects: 3
Study 7647718 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-depressed pain patients
Number of subjects: 3
Study 7647718 — intervention group
Group type: COMPARATOR
Intervention: Non-pain control subjects
Number of subjects: 3
Study 2754771 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal tetanus vaccination during pregnancy
Number of subjects: 0
Study 2754771 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight as an indicator
Number of subjects: 0
Study 371317 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexon
Number of subjects: 20
Study 371317 — intervention group
Group type: COMPARATOR
Intervention: chromic catgut-Mersilene
Number of subjects: 20
Study 31823482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid trial designs combining RCTs and RWD
Number of subjects: 0
Study 31823482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid trial designs
Number of subjects: 0
Study 31823482 — intervention group
Group type: EXPERIMENTAL
Intervention: RWE from observational studies
Number of subjects: 0
Study 31823482 — intervention group
Group type: EXPERIMENTAL
Intervention: RWE
Number of subjects: 0
Study 31399742 — intervention group
Group type: EXPERIMENTAL
Intervention: High cyclic temperature group (HT, 29‐35°C, ad libitum)
Number of subjects: 216
Study 31399742 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral group (TC, 21 ± 1°C, ad libitum)
Number of subjects: 216
Study 31399742 — intervention group
Group type: EXPERIMENTAL
Intervention: Pair-feeding group (PF, 21 ± 1°C, pair-feeding on the daily feed intake of HT hens)
Number of subjects: 216
Study 31399742 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between feed intake and principal coordinate 1 (PC1) in PCoA
Number of subjects: 216
Study 31399742 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear discriminant analysis
Number of subjects: 216
Study 28085913 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training and nutrition group (PTN, n = 39)
Number of subjects: 80
Study 28085913 — intervention group
Group type: COMPARATOR
Intervention: Social support group (SoSu, n = 41)
Number of subjects: 80
Study 26047409 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 0
Study 26047409 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 0
Study 26047409 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative neurological deterioration
Number of subjects: 0
Study 24053695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecologically valid strategy training
Number of subjects: 100
Study 24053695 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 100